A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 42
Summary
- Conditions
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This will be a multicenter, non-randomized, open-label phase II clinical trial.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03070301
- Collaborators
- Novartis
- Dana-Farber Cancer Institute
- M.D. Anderson Cancer Center
- Investigators
- Principal Investigator: Diane Reidy-Lagunes, MD, MS Memorial Sloan Kettering Cancer Center
Get Well Soon